Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of CLL; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of CLL. Consensus recommendations based on available evidence are presented for the first-line treatment of CLL.

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia

We would like to express our thanks to the hematologists and medical oncologists who provided their clinical expertise throughout the development of these guidelines:

Dr. Carolyn Owen, Hematologist, Foothills Medical Centre, Alberta.

Dr. Versha Banerji, Hematologist, Cancer Care Manitoba, Manitoba.

Dr. Nathalie Johnson, Hematologist, Jewish General Hospital, Quebec.

Dr. Alina Gerrie, Hematologist, Centre for Lymphoid Cancer, British Columbia.

Dr. Andrew Aw, Hematologist, The Ottawa Hospital, Ontario.

Dr. Christine Chen, Hematologist, University of Toronto, and Princess Margaret Cancer Centre, Ontario.

Dr. Sue Robinson, Hematologist Dalhousie University and QEII Health Sciences Centre, Nova Scotia.


Lymphoma Canada and specialists are currently in the process of developing the relapsed/refractory treatment guideline.




Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!